Endothelin-1 receptor antagonists in fetal development and pulmonary arterial hypertension.
Reprod Toxicol
; 56: 45-51, 2015 Aug 15.
Article
en En
| MEDLINE
| ID: mdl-26111581
The Pregnancy Prevention Program (PPP) is in place to prevent drug-induced developmental malformations. Remarkably, among the ten PPP-enlisted drugs are three endothelin-1 (ET-1) receptor antagonists (ERA's: ambrisentan, bosentan and macitentan), which are approved for the treatment of Pulmonary Arterial Hypertension (PAH). This review describes the effects of ERA's in PAH pathobiology and cardiopulmonary fetal development. While ERA's hamper pathological remodeling of the pulmonary vasculature and as such exert beneficial effects in PAH, they disturb fetal development of cardiopulmonary tissues. By blocking ET-1-mediated positive inotropic effects and myocardial fetal gene induction, ERA's may affect right ventricular adaptation to the increased pulmonary vascular resistance in both the fetus and the adult PAH patient.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Complicaciones Cardiovasculares del Embarazo
/
Arteria Pulmonar
/
Receptores de Endotelina
/
Endotelina-1
/
Feto
/
Antagonistas de los Receptores de Endotelina
/
Hipertensión Pulmonar
/
Antihipertensivos
Tipo de estudio:
Etiology_studies
/
Risk_factors_studies
Límite:
Animals
/
Female
/
Humans
/
Pregnancy
Idioma:
En
Revista:
Reprod Toxicol
Asunto de la revista:
EMBRIOLOGIA
/
MEDICINA REPRODUTIVA
/
TOXICOLOGIA
Año:
2015
Tipo del documento:
Article
País de afiliación:
Países Bajos
Pais de publicación:
Estados Unidos